Bag “FDA to give emergency permission to ‘Remdesivir’ to cure Corona 19”

Anthony Pouch, director of the National Institute of Allergic Epidemics (NIAID), said the United States Food and Drug Administration (FDA) hopes to authorize the emergency use of the Ebola remedy “Remdesivir” to treat new coronavirus infections ( crown19).

According to CNN on the 30th (local time), Dr. Pouch, a key member of the United States White House Corona 19 (TF) Task Force, said: “The FDA has not yet made a final decision.” .

Even before appearing on NBC’s “Today Show” the day before, US pharmaceutical company Gilead Sciences, which makes Remdesivir, said it is trying to “get as much as possible and make the most of it.”

“The good news has come from the Remdesivir clinical trial,” Dr. Pouch said at the White House briefing on the 29th, suggesting that Remdesivir could be the first Corona19 treatment to approve the US government clinical trial.
Gilead Sciences announced today that Remdesibir has met NIAID’s primary objective. However, the White House was said to reveal the details. NIAID conducted a clinical trial of Ramdesivir in 1,063 Corona19 patients worldwide.

In the clinical trial, the director of the exchange explained that Corona19 patients who took Remdesivir recovered after an average of 11 days, while patients who took the control group, false Ramdesivir, recovered after an average of 15 days.

The 4-day average recovery is faster when taking remedyvir. “The results of clinical trials showed that Ramdesivir clearly had a positive effect in reducing recovery time,” said Pouch.

However, it has not been confirmed whether Remdesivir can reduce the crown mortality rate19. In NIAID clinical trials, the mortality rate for patients taking ramdesivir was 8%, and the mortality rate for patients taking simulated ramdesibir was 11.6%.

“The mortality reduction effect of Remedyvir has not yet reached a statistically significant result,” he said.

The exchange’s director said the full results of the NIAID trials will be published in the medical journal sooner or later. “This may be the standard of care.”

Gilead said that his own clinical trials in 397 severely corona patients19 showed an improvement of at least 50% of the patients who took Remedyvir for 5 days.

Furthermore, patients taking Remdecivir were reported to achieve similar improvements to those who had been treated for 10 days in different ways, and there were no safety concerns.

However, this clinical trial has limitations in interpretation, such as not knowing how many patients were cured, because there is no control group that has not taken remedyvir.

Additionally, Gilead is conducting a clinical trial of Remdevisir in patients with mild crown19. The results of this experiment have not been published.